Dr. Tom Tu
Justin Crockett joined Inari Medical in November 2020 as Vice president of Inari Solutions Group and brings with him over 20 years of marketing, clinical, and commercial management experience. Justin joined Inari Medical from Boston Scientific, where he served as Vice President of U.S. Healthcare Solutions leading commercial solutions across the Cardiac Rhythm Management Division and the Interventional Cardiology Group. Prior to Boston Scientific, Justin served in multiple sales and marketing roles with St. Jude Medical (acquired by Abbott) and Pfizer Pharmaceuticals. Justin holds a Bachelor of Business Administration from the University of Mississippi, an MBA from the University of Southern Mississippi, and a doctorate degree from the Medical University of South Carolina. Justin also is a Lecturer of Health Administration at New York University.
Vitas brings nearly 20 years of medical device sales and marketing expertise to Inari. Prior to joining Inari Vitas spent 14 years with Medtronic’s Neurovascular business. He joined that business when it was a small start-up called Micro Therapeutics, and grew with the organization as it became ev3, Covidien, and eventually, Medtronic. From 2006 on, he held multiple Marketing roles of increasing responsibility and launched its pivotal Acute Ischemic Stroke platform globally. In 2014 Vitas moved to Singapore, where under Covidien he led the Marketing organization for Vascular Therapies across Asia. In 2016, under Medtronic, Vitas became the General Manager for the Neurovascular business across Asia Pacific. Prior to his Neurovascular experience Vitas spent time with Applied Medical in the laparoscopic surgery arena and other start-up biotechnology ventures. Vitas holds a B.A in Political Science and History from McGill University, and an MBA from the University of California, Irvine.
Eric has more than 18 years of medical device experience, holding various positions in manufacturing, manufacturing support, engineering, and leadership. Eric has a proven record of scaling new products to high volume output with world-class quality and reliability, as well as developing and maintaining a robust product supply chain. Prior to joining Inari in 2014, Eric held several engineering positions at SenoRx Inc. and Bard Peripheral Vascular (which acquired SenoRx in 2010).
Janet joined Inari Medical as an Outsourced Controller in March of 2015. Bringing over 25 years of financial knowledge and expertise, Janet was promoted to Senior Director of Finance and Accounting in March of 2019, leading all aspects of the financial transaction and reporting processes. Prior to joining Inari Medical, Janet founded Byk & Associates, Inc., serving as an outsourced controller for life science start-ups in Orange County for 17 years, after spending 10 years in EY’s audit practice. She earned a BS in Accounting from California State University-Long Beach - College of Business and is a Certified Public Accountant.
Angela has over 20 years of public company legal experience. Prior to joining Inari, Angela served as the Deputy General Counsel of CoreLogic, Inc., where she held various roles including overseeing the corporate governance, M&A and securities functions. Angela also served as a senior associate at Latham & Watkins, LLP and Fried Frank, where she advised clients on corporate transactions, including equity and debt financings. Her private practice experience included five years in London, England during which time she advised corporate and investment banking clients on financing transactions. She earned a BA in French from Stetson University and a JD from the University of Florida.
Kevin brings over 15 years of medical device experience in corporate development (M&A and venture capital), strategy, finance and sales. Most recently, Kevin was the Director of Business Development for the Peripheral Interventions division of Boston Scientific, where he helped transform the business from $1B of annual sales to over $1.7B. Kevin’s deal experience spans multiple acquisitions, divestitures and venture investment transactions, including the $4.2B acquisition of BTG and the $160M acquisition of Veniti. Prior to Boston Scientific, Kevin worked as an equity research analyst at Wells Fargo Securities and Bank of America Merrill Lynch covering the medical device sector. Kevin started his career in medical devices in the Cardiac Rhythm Management division of Medtronic. Kevin holds a BS in Biology from Davidson College and a Masters of Business Administration from New York University’s Stern School of Business.